Sudden Regulatory Shift

FDA testosterone panel recommendations spark concern

Concerns Over Sudden Regulatory Shift

The FDA’s December 2025 expert panel has recommended sweeping changes to testosterone regulation – a sharp departure from the agency’s long-standing cautionary stance for the hormone.

The panel urged the FDA to broaden testosterone replacement therapy (TRT) eligibility, remove prostate-cancer related warnings, reclassify testosterone so it is no longer a controlled substance, and promote routine screening for low testosterone in all men.

These recommendations conflict with a decade of FDA policy and go far beyond what current evidence supports.

While the TRAVERSE trial showed no increased risk of heart attack or stroke in men with clinically diagnosed hypogonadism, it did not evaluate the safety of TRT for age-related declines in testosterone – the very group panelists suggested expanding use to.

Regulatory experts warn that the panel’s conclusions echo a broader pattern in federal health agencies under current leadership. Major decisions are being made without transparent scientific processes, are inconsistent with established norms, and are potentially aligned more with political messaging than evidence.

Public health analysts emphasize that testosterone therapy remains appropriate and beneficial for men with documented hypogonadism but warn that mass-market expansion – especially without controlled-substance oversight – risks misuse, dependency, and increased cardiovascular complications from elevated blood pressure.

The FDA has not yet adopted the panel’s recommendations. Further updates are expected in early 2026.